Jack M Roth

US Patent:

6410010, Jun 25, 2002

Filed:

Oct 29, 1993

Appl. No.:

08/145826

Inventors:

Wei-Wei Zhang - Sugar Land TX
Jack A Roth - Houston TX

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

A61K 4800

US Classification:

424 932, 424 931, 424 936, 4353201

Abstract:

Described are simplified and efficient methods for preparing recombinant adenovirus using liposome-mediated cotransfection and the direct observation of a cytopathic effect (CPE) in the transfected cells. Also disclosed are compositions and methods involving novel p53 adenovirus constructs, including methods for restoring p53 function and tumor suppression in cells and animals having abnormal p53.

US Patent:

6410029, Jun 25, 2002

Filed:

Jul 9, 1999

Appl. No.:

09/351191

Inventors:

Tapas Mukhopadhyay - Houston TX
Jack A. Roth - Houston TX

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

A61K 3900

US Classification:

4241981, 514 44, 530350, 435 701, 435325, 4353201, 435455

Abstract:

The present invention details methods for the treatment of cancer. In particular, it concerns the induction of apoptosis of cancer cells following treatment with methoxyestradiol. 2-methoxyestradiol (2-MeOE ) increase wild-type p53 levels in a human non-small lung cancer cell lines associated with accumulation of cyclin dependent kinase inhibitor p21 WAF1/CIP1. Significant apoptotic cell death occurred after the drug treatment. Thus, 2-MeOE facilitates induction of p53-mediated apoptosis.

US Patent:

6436700, Aug 20, 2002

Filed:

Dec 7, 1992

Appl. No.:

07/987235

Inventors:

Jack A. Roth - Houston TX
Tapas Mukopadhyay - Houston TX
Michael Tainsky - Houston TX

Assignee:

Board of Regents, The University of Texas Systems - Austin TX

International Classification:

C12N 1500

US Classification:

4353201, 536 245

Abstract:

Disclosed are methods and compositions for the selective inhibition gene expression through the application of antisense RNA technology. Antisense RNA constructs of the present invention employ the use of antisense intron DNA corresponding to distinct intron regions of the gene whose expression is targeted for down-regulation. In an exemplary embodiment, a human lung cancer cell line (NCI-H460a) with a homozygous spontaneous K-ras mutation was transfected with a recombinant plasmid that synthesizes a genomic segment of K-ras in antisense orientation. Translation of the mutated K-ras mRNA was specifically inhibited, whereas expression of H-ras and N-ras was unchanged. A three-fold growth inhibition occurred in H460a cells when expression of the mutated ras p21 protein was down-regulated by antisense RNA and cells remained viable. The growth of H460a tumors in nu/nu mice was substantially reduced by expressed K-ras antisense RNA.

US Patent:

6482803, Nov 19, 2002

Filed:

Sep 1, 1995

Appl. No.:

08/523030

Inventors:

Jack A. Roth - Houston TX
De Wei Cai - Cheltenham PA
Tapas Mukhopadhyay - Houston TX

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

C07H 2100

US Classification:

514 44, 435 691, 435 9131, 4353201, 435375, 536 232, 536 245

Abstract:

The present invention discloses expression constructs and methods for employing them that result in the modulation of abnormal oncogene and tumor suppressor genes in a novel approach to cancer prevention and therapy. In one embodiment, an expression construct expresses a ribozyme that inactivates mutant p53 and also expresses the functional p53.

US Patent:

6511847, Jan 28, 2003

Filed:

Sep 21, 2000

Appl. No.:

09/668532

Inventors:

Wei-Wei Zhang - Sugar Land TX
Jack A Roth - Houston TX

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

C12N 15861

US Classification:

4353201, 4352351, 435 691, 536 231, 536 2372, 536 241

Abstract:

Described are simplified and efficient methods for preparing recombinant adenovirus using liposome-mediated cotransfection and the direct observation of a cytopathic effect (CPE) in the transfected cells. Also disclosed are compositions and methods involving novel p53 adenovirus constructs, including methods for restoring p53 function and tumor suppression in cells and animals having abnormal p53.

US Patent:

6627189, Sep 30, 2003

Filed:

Jun 2, 1995

Appl. No.:

08/459699

Inventors:

Jack A. Roth - Houston TX
Tapas Mukopadhyay - Houston TX
Michael Tainsky - Houston TX

Assignee:

Board of Regents, The University of Texas Systems - Austin TX

International Classification:

A01N 6300

US Classification:

424 932, 514 44

Abstract:

Disclosed are methods and compositions for the selective inhibition gene expression through the application of antisense RNA technology. Antisense RNA constructs of the present invention employ the use of antisense intron DNA corresponding to distinct intron regions of the gene whose expression is targeted for down-regulation. In an exemplary embodiment, a human lung cancer cell line (NCI-H460a) with a homozygous spontaneous K-ras mutation was transfected with a recombinant plasmid that synthesizes a genomic segment of K-ras in antisense orientation. Translation of the mutated K-ras mRNA was specifically inhibited, whereas expression of H-ras and N-ras was unchanged. A three-fold growth inhibition occurred in H460a cells when expression of the mutated ras p21 protein was down-regulated by antisense RNA and cells remained viable. The growth of H460a tumors in nu/nu mice was substantially reduced by expressed K-ras antisense RNA.

US Patent:

6630344, Oct 7, 2003

Filed:

Aug 29, 2000

Appl. No.:

09/650946

Inventors:

Bingliang Fang - Houston TX
Jack A. Roth - Houston TX

Assignee:

Texas Systems, University of the Board of Regents - Austin TX

International Classification:

C12N 15861

US Classification:

4353201, 536 235, 536 2372, 536 241

Abstract:

The present invention provides viral vectors that have been engineered to contain a synthetic promoter that controls at least one essential gene. The synthetic promoter is induced by a specific gene product not normally produced in the cells in which the viral vector is to be transferred. The vectors are propagated in producer or helper cells that express the inducing factor, thereby permitting the virus to replicate to high titer. The lack of the inducing factor in the target cells precludes viral replication, however, meaning that no vector toxicity or immunogenicity arises. Where the virus carries a gene of interest, this should provide for higher level expression for longer periods of time than with current vectors. Methods for making the vectors, helper cells, and their use in protein production, vaccines and gene therapy are disclosed.

US Patent:

6740320, May 25, 2004

Filed:

Jun 2, 1995

Appl. No.:

08/459713

Inventors:

Wei-Wei Zhang - Sugar Land TX
Jack A. Roth - Houston TX

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

A61K 4800

US Classification:

424 932, 424 931, 424 936, 435 691, 4353201, 435455, 435456

Abstract:

Described are simplified and efficient methods for preparing recombinant adenovirus using liposome-mediated cotransfection and the direct observation of a cytopathic effect (CPE) in the transfected cells. Also disclosed are compositions and methods involving novel p53 adenovirus constructs, including methods for restoring p53 function and tumor suppression in cells and animals having abnormal p53.